The association of COVID-19 to cardiopathies generates systemic inflammation due to dysregulation linked to angiotensin-converting enzyme overexpression 2 (ACE2) and elevation of cardiac injury biomarkers [47,48]; in addition, the virus can cause myocardial dysfunction, which aggravates the clinical condition. This evidence concerns the gene ACE2 and COVID-19.